The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
about
BRAF vs RAS oncogenes: are mutations of the same pathway equal? Differential signalling and therapeutic implicationsMulticenter, real-life experience with checkpoint inhibitors and targeted therapy agents in advanced melanoma patients in SwitzerlandMUG-Mel2, a novel highly pigmented and well characterized NRAS mutated human melanoma cell line.Correlation of somatic mutations and clinical outcome in melanoma patients treated with Carboplatin, Paclitaxel, and sorafenibCorrelation of BRAF and NRAS mutation status with outcome, site of distant metastasis and response to chemotherapy in metastatic melanoma.Genotyping of cutaneous melanoma.BRAF V600E mutation in early-stage multiple myeloma: good response to broad acting drugs and no relation to prognosisEstrogen Receptor β Agonists Differentially Affect the Growth of Human Melanoma Cell Lines.Analysis of BRAF and NRAS Mutation Status in Advanced Melanoma Patients Treated with Anti-CTLA-4 Antibodies: Association with Overall Survival?Molecular stratification of metastatic melanoma using gene expression profiling: Prediction of survival outcome and benefit from molecular targeted therapy.Cutaneous Melanoma with Brain Metastasis: Report of 193 Patients with New Observations.Is immunohistochemistry of BRAF V600E useful as a screening tool and during progression disease of melanoma patients?Acyl protein thioesterase 1 and 2 (APT-1, APT-2) inhibitors palmostatin B, ML348 and ML349 have different effects on NRAS mutant melanoma cellsGenomic medicine for cancer prognosis.The Rapid Emergence of Novel Therapeutics in Advanced Malignant Melanoma.Integrative network and transcriptomics-based approach predicts genotype- specific drug combinations for melanoma.Prognostic and predictive biomarkers in melanoma: an update.Zebrafish as a Model Organism for the Development of Drugs for Skin Cancer.Pharmacological Inhibition of Myocardin-related Transcription Factor Pathway Blocks Lung Metastases of RhoC-Overexpressing Melanoma.NF1-mutated melanoma tumors harbor distinct clinical and biological characteristics.Metastatic pathways in patients with cutaneous melanoma.Prognostic significance of BRAF and NRAS mutations in melanoma: a German study from routine care.Prognostic relevance of lactate dehydrogenase and serum S100 levels in stage IV melanoma with known BRAF mutation status.Detection of BRAF, NRAS, KIT, GNAQ, GNA11 and MAP2K1/2 mutations in Russian melanoma patients using LNA PCR clamp and biochip analysis.The role of BRAF mutations in primary melanoma growth rate and survival.Tumour mutation status and sites of metastasis in patients with cutaneous melanoma.Ultraviolet radiation accelerates NRas-mutant melanomagenesis: A cooperative effect blocked by sunscreen.The Prognostic Value of HRAS mRNA Expression in Cutaneous Melanoma.BRAF and MEK Inhibitors Influence the Function of Reprogrammed T Cells: Consequences for Adoptive T-Cell Therapy.Polo-like kinase-1 immunoreactivity is associated with metastases in cutaneous melanoma.Is BRAF a prognostic factor in stage III skin melanoma? A retrospective study of 72 patients after positive sentinel lymph node dissection.Prognostic and predictive values of oncogenic BRAF, NRAS, c-KIT and MITF in cutaneous and mucous melanoma.Molecular pathology of cutaneous melanoma
P2860
Q28543370-8525D4FC-AB3A-4C37-8639-8A3AB471C058Q30491702-D1AC7A52-F438-489E-AAD7-278F463844CCQ33704699-6D89EE36-FF0C-4BAE-AD46-D773085808B1Q33758211-D2292CA8-84E3-4BFC-8F66-B8610441130BQ33918101-79779803-80B1-45CA-8117-03FBCA502BE7Q34667738-64EDD2A9-09D8-43AA-A1A8-7704BA1F430CQ35244900-0292C352-C4F0-46A6-BDC3-29744DC2FF5DQ35725686-4FD91E17-08D7-4D3A-9931-A92A48DB9B0EQ35794989-4EF256F5-FF93-4CA8-AE8E-9BAF2D3E9AAAQ35828560-03964101-9EE5-44C2-ACE0-D152B74C7CB6Q36026232-4591FC0D-8341-41BB-BD2B-D067783DD926Q36198169-0E56C0D1-00DA-46FD-901A-E4A8F0E6CF9FQ36916468-01200DBE-D95A-4DC3-95FA-BB8B30CAA89DQ38238835-1AD176AC-6E72-4758-80A4-E3633B25B5AFQ38589776-FE924A14-DB67-4308-8A59-CF7A148851BFQ38621140-2E60E34E-69B7-4236-B1BE-6B9A23C93CEDQ38653619-1E62B6F0-B165-4204-BDBF-EB65E0378CF3Q38656012-363D0AE3-38E9-47CB-A690-4148578D3812Q38731620-E520AD64-DFBF-441F-BA66-6C61BBC60FE7Q38925098-53AEF894-357C-4F02-9A5D-93BE540E97DFQ39024316-11437C77-CEC8-4433-B4D7-E5ECCC239BF0Q40087210-C78DB5A5-A6BF-4AE1-9CFF-0A59023285EBQ41056748-F9C7DDB7-3DF3-40DA-A7C8-08ACEBA2EF08Q41592696-596565F7-29C0-4CDF-BCBB-DA6A9873A18FQ47206923-EFF824C6-3039-44B6-94F8-4D2063FF6268Q47978745-3EC6C4F8-8889-4D16-B5A5-BB2162277A4DQ48092505-A6AC1F69-F14F-40B5-9315-F0ED74BC0963Q48213688-1F5768BA-C9E5-4F52-B2BB-4D9AAF3F4019Q48218708-8B84E691-57C8-4BE2-B19C-DA2E52D78CE0Q48260681-477AC2CF-2AD7-4DA1-9B20-1413F7ABF311Q50713886-D01201E3-7DF6-4A36-AF2F-F5E9F1DE198FQ55068437-68CA9519-7864-4106-9A90-A40B0645022BQ56428911-F4668C04-B259-409C-8486-EE1825AFE059
P2860
The clinical significance of BRAF and NRAS mutations in a clinic-based metastatic melanoma cohort.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
The clinical significance of B ...... ed metastatic melanoma cohort.
@en
The clinical significance of B ...... ed metastatic melanoma cohort.
@nl
type
label
The clinical significance of B ...... ed metastatic melanoma cohort.
@en
The clinical significance of B ...... ed metastatic melanoma cohort.
@nl
prefLabel
The clinical significance of B ...... ed metastatic melanoma cohort.
@en
The clinical significance of B ...... ed metastatic melanoma cohort.
@nl
P2093
P356
P1476
The clinical significance of B ...... sed metastatic melanoma cohort
@en
P2093
A Carneiro
H Cirenajwis
L Lundgren
P304
P356
10.1111/BJD.12504
P407
P577
2013-11-01T00:00:00Z